Perm Medical JournalPerm Medical JournalПермский медицинский журнал (сетевое издание "Perm medical journal")0136-14492687-1408Eco-Vector54603310.17816/pmj405167-177Biology and experimental medicineБиология и экспериментальная медицинаResearch ArticleAcute post-manipulation pancreatitis after interventions on the major duodenal papilla (experimental study)Острый постманипуляционный панкреатит после вмешательств на большом дуоденальном сосочке (экспериментальное исследование)https://orcid.org/0009-0001-6515-72317422-3786RantsevM. A.РанцевМ. А.
Russian Federation

Candidate of Medical Sciences, Associate Professor, Department of Surgery, Coloproctology and Endoscopy

кандидат медицинских наук, доцент кафедры хирургии, колопроктологии и эндоскопии

r-ma@bk.ruPrudkovM. I.ПрудковМ. И.
Russian Federation

MD, PhD, Professor, Chief Non-Staff Surgeon of the Ural Federal District, Head of the Department of Surgery, Coloproctology and Endoscopy

доктор медицинских наук, профессор, главный внештатный хирург Уральского Федерального округа, заведующий кафедрой кафедры хирургии, колопроктологии и эндоскопии

r-ma@bk.ruChupakhinO. N.ЧупахинО. Н.
Russian Federation

Doctor of Chemical Sciences, Academician of RAS, Chief Scientist

доктор химических наук, академик РАН, научный руководитель

r-ma@bk.ruUral State Medical UniversityУральский государственный медицинский университетI.Ya. Postovsky Institute of Organic Synthesis of the Ural Branch of RASИнститут органического синтеза имени И.Я. Постовского Уральского отделения академии наук России1810202340516717712072023Copyright ©; 2023, Eco-VectorCopyright ©; 2023, Эко-Вектор2023Eco-VectorЭко-Векторhttps://permmedjournal.ru/PMJ/article/view/546033

Objective. To study the morphological consequences of severe acute post-manipulation pancreatitis (APP), the morphological features of its course and the result of the compound "L-17" exposure.

Materials and methods. Rats weighing 250–300 g were used. Forty operations were performed to create a model of APP on rats. The control group included 20 rats with APP without medication, the experimental group – 20 rats with AKI against the background of "L-17" introduced in the dose of 40 mg/kg once per day.

Results. In all cases of application of this APP model in rats, the development of acute pancreatitis was noted. The conducted morphological studies showed that APP in rats in the experiment met the criteria for a severe course of acute pancreatitis with the development of purulent peritonitis and necrotizing parapancreatitis with morphological manifestations of systemic inflammation in all the organs studied (with a lethality of 70 %). The use of a new "L-17" in APP in experimental rats showed a decrease in the risk for developing both purulent peritonitis and purulent-necrotic parapancreatitis as well as a 2-fold decrease in mortality (from 70 % to 30 %). A new effect of "L-17" was revealed, i.e. prevention of necrosis of Langerhans islets. The study of the cellular composition of the inflammatory infiltrate showed a decrease in the activity of inflammatory process.

Conclusions. The efficacy of a new rat model of APP, ranked by severity, was shown. "L-17" alleviates the severity of APP, reducing the risk for developing various purulent complications and systemic inflammation.

Цель. Исследовать морфологические проявления и особенности воздействия соединения «L-17» на течение острого постманипуляционного панкреатита тяжелой степени в эксперименте.

Материалы и методы. Использованы крысы массой 250–300 г. Проведено 40 операций по созданию модели ОПП на крысах. В группу контроля вошло 20 крыс с ОПП без медикаментозного воздействия. В экспериментальную группу – 20 крыс с ОПП на фоне введения «L-17» в дозе 40 мг/кг один раз в сутки.

Результаты. Во всех случаях применения данной модели ОПП у крыс отмечено развитие острого панкреатита. Проведенные морфологические исследования показали соответствие ОПП у крыс в эксперименте критериям тяжелой степени течения острого панкреатита, с развитием гнойного перитонита и некротического парапанкреатита с морфологическими проявлениями системного воспаления во всех исследованных органах (с летальностью 70 %). Применение нового «L-17» при ОПП у крыс в эксперименте показало уменьшение риска развития как гнойного перитонита, так и гнойно-некротического парапанкреатита, снижение летальности в 2 раза (с 70 до 30 %). Выявлен новый эффект «L-17» – предупреждение некроза островков Лангерганса. Исследование клеточного состава воспалительного инфильтрата показало снижение активности воспалительного процесса.

Выводы. Показана эффективность новой ранжированной по степени тяжести модели ОПП на крысах. Соединение «L-17» облегчает тяжесть течения ОПП, снижая риск развития различных гнойных осложнений и системного воспаления.

acute post-manipulation pancreatitisexperimental pancreatitispost-cannulation pancreatitissubsti-tuted thiadiazinesL-17 compoundострый постманипуляционный панкреатитэкспериментальный панкреатитпостканюляционный панкреатитзамещенные тиадиазинысоединение L-17Karyampudi A., Nabi Z., Reddy D.N. Risk Factors and Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis: An Update. EMJ. 2021; 6 (4): 96–108.Akshintala V.S., Goenka M.K., Kamal A., Rai V.K., Ghosh S., Talukdar R., Khashab M.A., Kalloo A.N., Reddy D.N., Singh V., Dhaka N., Sinha S., Kochha R. Sa 1386 Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High-Risk Patients: Secondary Analysis of a Randomized Controlled Study. GIE. 2017; 85 (5): AB219-AB220. DOI: 10.1016/j.gie.2017.03.489Akshintala V.S., Goenka M.K., Kamal A., Rai V.K., Ghosh S., Talukdar R., Khashab M.A., N. Kalloo A.N., Reddy D.N., Singh V., Dhaka N., Sinha S., Kochha R. Sa 1386 Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High-Risk Patients: Secondary Analysis of a Randomized Controlled Study. GIE. 2017; 85 (5): AB219-AB220. DOI: 10.1016/j.gie.2017.03.489Cahyadi O., Tehami N., de-Madaria E., Siau K. Post-ERCP Pancreatitis: Prevention, Diagnosis and Management. Medicina (MDPI) 2022; 58 (9): 1261. DOI: 10.3390/medicina58091261Cahyadi O., Tehami N., de-Madaria E., Siau K. Post-ERCP Pancreatitis: Prevention, Diagnosis and Management. Medicina (MDPI). 2022; 58 (9): 1261. DOI: 10.3390/medicina58091261Freeman M.L., DiSario J.A., Nelson D.B., Fennerty M.B., Lee J.G., Bjorkman D.J., Overby C.S., Aas J., Ryan M.E., Bochna G.S., Shaw M.J., Snady H.W., Erickson R.V., Moore J.P., Roel J.P. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54 (4): 425–34. DOI: 10.1067/mge.2001.117550Freeman M.L., DiSario J.A., Nelson D.B., Fennerty M.B., Lee J.G., Bjorkman D.J., Overby C.S., Aas J., Ryan M.E., Bochna G.S., Shaw M.J., Snady H.W., Erickson R.V., Moore J.P., Roel J.P. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001; 54 (4): 425–34. DOI: 10.1067/mge.2001.117550Mohammed A.O., Ahmed E.A.,Mohammed A.O., Ahmed E.A., Omar A.S., Hussein El-A. Risk factors for post-ERCP pancreatitis a prospective multicenter study in Upper Egypt. Egypt J Surg. 2015; 34 (1): 1–10. DOI: 10.4103/1110-1121.153364Omar A.S., Hussein El-A. Risk factors for post-ERCP pancreatitis a prospective multicenter study in Upper Egypt. Egypt J Surg. 2015; 34 (1): 1–10. DOI: 10.4103/1110-1121.153364Perdigoto D.N., Gomes D., Almeida N., Mendes S., Alves A.R., Camacho E., Tomé L. Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in the Indomethacin Era – A Prospective Study. GE Port J Gastroenterol. 2019; 26 (3): 176–183. DOI: 10.1159/000492313Perdigoto D.N., Gomes D., Almeida N., Mendes S., Alves A.R., Camacho E., Tomé L. Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in the Indomethacin Era – A Prospective Study. GE Port J Gastroenterol. 2019; 26 (3): 176–183. DOI: 10.1159/000492313Ribeiro I.B., Silvino do Monte Junior E., Neto A.A. M., Proença I.M., Hourneaux de Moura D.T., Minata M.K., Ide E., Lera dos Santos M.E., Luz G.O., Matuguma S.E., Cheng S., Baracat R., Hourneaux de Moura E.G. Pancreatitis after endoscopic retrograde cholangiopancreatography: A narrative review. World J Gastroenterol. 2021; 27 (20): 2495–2506. DOI: 10.3748 % 2Fwjg.v27.i20.2495Ribeiro I.B., Silvino do Monte Junior E., Neto A.A. M., Proença I.M., Hourneaux de Moura D.T., Minata M.K., Ide E., Lera dos Santos M.E., Luz G.O., Matuguma S.E., Cheng S., Baracat R., Hourneaux de Moura E.G. Pancreatitis after endoscopic retrograde cholangiopancreatography: A narrative review. World J Gastroenterol. 2021; 27 (20): 2495–2506. DOI: 10.3748 % 2Fwjg.v27.i20.2495Syrén E., Eriksson S., Enochsson L., Eklund A., Sandblom G. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography. BJS Open. 2019; 3 (4): 485–489. DOI: 10.1002/bjs5.50162Syrén E., Eriksson S., Enochsson L., Eklund A., Sandblom G. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography. BJS Open. 2019; 3 (4): 485–489. DOI: 10.1002/bjs5.50162Cotton P.B., Garrow D.A., Gallagher J., Romagnuolo J. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc. 2009; 70 (1): 80–88. DOI: 10.1016/j.gie.2008.10.039Cotton P.B., Garrow D.A., Gallagher J., Romagnuolo J. Risk factors for complica-tions after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc. 2009; 70 (1): 80–88. DOI: 10.1016/j.gie.2008.10.039Anderson M.A., Fisher L., Jain R., Evans J.A., Appalaneni V., Ben-Menachem T., Cash B.D., Decker G.A., Early D.S., Fanelli R.D. Complications of ERCP. Gastrointest Endosc. GIE. 2012; 75 (3): 467–473. DOI: 10.1016/Anderson M.A., Fisher L., Jain R., Evans J.A., Appalaneni V., Ben-Menachem T., Cash B.D., Decker G.A., Early D.S., Fanelli R.D. Complications of ERCP. Gastrointest Endosc. GIE. 2012; 75 (3): 467–473. DOI: 10.1016/j.gie.2011.07.010j.gie.2011.07.010Matsubayashi H., Fukutomi A., Kanemoto H., Maeda A., Matsunaga K., Uesaka K., Otake Y., Hasuike N., Yamaguchi Y., Ikehara H., Kohei Takizawa K., Yamazaki K., Ono H. Risk of pancreatitis after endoscopic retrograde cholangiopancreatography and endoscopic biliary drainage. HPB (Oxford). 2009; 11 (3): 222–228. DOI: 10.1111 % 2Fj.1477-2574.2008.00020.xMatsubayashi H., Fukutomi A., Kanemoto H., Maeda A., Matsunaga K., Uesaka K., Otake Y., Hasuike N., Yamaguchi Y., Ikehara H., Kohei Takizawa K., Yamazaki K., Ono H. Risk of pancreatitis after endoscopic retrograde cholangiopancreatography and endoscopic biliary drainage. HPB (Oxford). 2009; 11 (3): 222–228. DOI: 10.1111 % 2Fj.1477-2574.2008.00020.xAndriulli A., Loperfido S., Napolitano G., Niro G., Valvano M.R., Spirito F., Pilotto A., Forlano R. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007; 102 (8): 1781–1788. DOI: 10.1111/j.1572-0241.2007.01279.xAndriulli A., Loperfido S., Napolitano G., Niro G., Valvano M.R., Spirito F., Pilotto A., Forlano R. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007; 102 (8): 1781–1788. DOI: 10.1111/j.1572-0241.2007.01279.xDubravcsik Z., Hritz I., Szepes A., Madácsy L. Risk factors of post-ERCP pancreatitis in high-risk patients despite prevention with prophylactic pancreatic stents. Scand J Gastroenterol. 2020; 55 (1): 95–99. DOI: 10.1080/00365521.2019.1701069Dubravcsik Z., Hritz I., Szepes A., Madácsy L. Risk factors of post-ERCP pancreatitis in high-risk patients despite prevention with prophylactic pancreatic stents. Scand J Gastroenterol. 2020; 55 (1): 95–99. DOI: 10.1080/00365521.2019.1701069Köseoğlu H., Solakoğlu T., Başaran M., Özer Sarı S., Tahtacı M., Yaman S., Selvi E., Ersoy O. Risk factors for post-ERCP pancreatitis: it depends on the ERCP indication. Acta Gastroenterol Belg. 2020; 83 (4): 598–602.Köseoğlu H., Solakoğlu T., Başaran M., Özer Sarı S., Tahtacı M., Yaman S., Selvi E., Ersoy O. Risk factors for post-ERCP pancreatitis: it depends on the ERCP indication. Acta Gastroenterol Belg. 2020; 83 (4): 598–602.Arslan U., Cayci H.M., Doğan G., Erdogdu U.E., Tardu A., Yiğit D., Firat Y.D., Şansal M. Post-ERCP complications, risk factors and management of complica-tions. Laparosc Endosc Surg Sci. 2021; 28 (2): 93–98. DOI:10.14744/less.2021.58966Arslan U., Cayci H.M., Doğan G., Erdogdu U.E., Tardu A., Yiğit D., Firat Y.D., Şansal M. Post-ERCP complications, risk factors and management of complications. Laparosc Endosc Surg Sci. 2021; 28 (2): 93–98. DOI: 10.14744/less.2021.58966Lin Y., Liu X., Cao D.-Q., Tang J.-H., Wen J.-J., Li T.-F., Liu P.-F., Xia T.-S. Analysis of risk factors and prevention strategies of post-ERCP pancreatitis. Eur Rev Med Pharmacol Sci. 2017; 21 (22): 5185–5190. DOI: 10.26355/eurrev_201711_13838Lin Y., Liu X., Cao D.-Q., Tang J.-H., Wen J.-J., Li T.-F., Liu P.-F., Xia T.-S. Analysis of risk factors and prevention strategies of post-ERCP pancreatitis. Eur Rev Med Pharmacol Sci. 2017; 21 (22): 5185–5190. DOI: 10.26355/eurrev_201711_13838Colton J.B., Curran C.C. Quality indicators, including complications, of ERCP in a community setting: a prospective study. Gastrointest Endosc. 2009; 70 (3): 457–67. DOI: 10.1016/j.gie.2008.11.022Colton J.B., Curran C.C. Quality indicators, including complications, of ERCP in a community setting: a prospective study. Gastrointest Endosc. 2009; 70 (3): 457–67. DOI: 10.1016/j.gie.2008.11.022Chen J.J., Wang X.M., Liu X.Q., Li W., Dong M., Suo Z.W., Ding P., Li Y. Risk factors for post-ERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years. Eur J Med Res. 2014; 19 (1): 26. DOI: 10.1186 % 2F2047-783X-19-26Chen J.J., Wang X.M., Liu X.Q., Li W., Dong M, Suo Z.W., Ding P., Li Y. Risk factors for post-ERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years. Eur J Med Res. 2014; 19 (1): 26. DOI: 10.1186 % 2F2047-783X-19-26Чупахин О.Н., Сидорова Л.П., Петрова Н.М. и др. Замещенные 5R1, 6R2 1,3,4-тиадиазин-2 амины и фармацевтические композиции в качестве фармакологически активных средств, обладающих антикоагулянтным и антиагрегантным действием. Патент РФ № 2 259 371, С2 МПК7 С 07 D 417/12, 417/04, A61 K 31/549, A61 P 7/02; Заявл. 05.05.2033; Опубл. 27.08.2009; Бюллетень № 24.Chupakhin O.N., Sidorova L.P., Petrova N.M., et al. Substituted 5R1, 6R2 1,3,4-thiadiazine-2 amines and pharmaceutical compositions as pharmacologically active agents with anticoagulant and antiaggregant effects. RF patent No. 2 259 371, C2 MPK7 C 07 D 417/12, 417/04, A61 K 31/549, A61 P 7/02; Appl. 05/05/2033; Published 08/27/2009; Bulletin No. 24 (in Russian).Грибунов Ю.П., Баранов Г.А., Давыдовская Т.И., Скалозуб О.И. Патоморфологическая оценка эффективности современной иммунотерапии хирургического сепсиса. Кремлевская медицина 2012; 2: 69–74.Gribunov Yu. P., Baranov G.A., Davydovskaya T.I., and Skalozub O.I. Pathomorphological assessment of modern immunotherapy effectiveness in surgical sepsis. Kremlin medicine 2012; 2: 69–74 (in Russian).Pioli P.D. Plasma Cells, the Next Generation: Beyond Antibody Secretion. Front. Immunol. 2019; 10: 2768. DOI: 10.3389/fimmu.2019.02768.Pioli P.D. Plasma Cells, the Next Generation: Beyond Antibody Secretion. Front. Immunol. 2019; 10: 2768. DOI: 10.3389/fimmu.2019.02768.Dang V.D., Hilgenberg E., Ries S., Shen P., Fillatreau S. From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr Opin Immunol 2014; 28: 77–83. DOI: 10.1016/j.coi.2014.02.009.Dang V.D., Hilgenberg E., Ries S., Shen P., Fillatreau S. From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr Opin Immunol 2014; 28: 77–83. DOI: 10.1016/j.coi.2014.02.009.